Progenitor cell release plus exercise to improve functional performance in peripheral artery disease

The PROPEL Study

Kathryn Domanchuk, Luigi Ferrucci, Jack M. Guralnik, Michael H. Criqui, Lu Tian, Kiang Liu, Douglas Losordo, James Stein, David Green, Melina Kibbe, Lihui Zhao, Brian Annex, Harris Perlman, Donald Lloyd-Jones, William Pearce, Doris Taylor, Mary M. McDermott

Research output: Contribution to journalArticle

Abstract

Functional impairment, functional decline, and mobility loss are major public health problems in people with lower extremity peripheral artery disease (PAD). Few medical therapies significantly improve walking performance in PAD. We describe methods for the PROgenitor cell release Plus Exercise to improve functionaL performance in PAD (PROPEL) Study, a randomized controlled clinical trial designed to determine whether granulocyte-macrophage colony stimulating factor (GM-CSF) combined with supervised treadmill walking exercise improves six-minute walk distance more than GM-CSF alone, more than supervised treadmill exercise alone, and more than placebo plus attention control in participants with PAD, respectively. PROPEL Study participants are randomized to one of four arms in a 2 by 2 factorial design. The four study arms are GM-CSF plus supervised treadmill exercise, GM-CSF plus attention control, placebo plus supervised exercise therapy, or placebo plus attention control. The primary outcome is change in six-minute walk distance at 12-week follow-up. Secondary outcomes include change in brachial artery flow-mediated dilation (FMD), change in maximal treadmill walking time, and change in circulating CD34. + cells at 12-week follow-up. Outcomes are also measured at six-week and six-month follow-up. Results of the PROPEL Study will have important implications for understanding mechanisms of improving walking performance and preventing mobility loss in the large and growing number of men and women with PAD.

Original languageEnglish (US)
Pages (from-to)502-509
Number of pages8
JournalContemporary Clinical Trials
Volume36
Issue number2
DOIs
StatePublished - Nov 2013
Externally publishedYes

Fingerprint

Peripheral Arterial Disease
Granulocyte-Macrophage Colony-Stimulating Factor
Stem Cells
Walking
Exercise
Placebos
Arm
Exercise Therapy
Brachial Artery
Dilatation
Lower Extremity
Randomized Controlled Trials
Public Health

Keywords

  • GM-CSF
  • Intermittent claudication
  • Peripheral vascular disease
  • Physical functioning
  • Stem cells

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Domanchuk, K., Ferrucci, L., Guralnik, J. M., Criqui, M. H., Tian, L., Liu, K., ... McDermott, M. M. (2013). Progenitor cell release plus exercise to improve functional performance in peripheral artery disease: The PROPEL Study. Contemporary Clinical Trials, 36(2), 502-509. https://doi.org/10.1016/j.cct.2013.09.011

Progenitor cell release plus exercise to improve functional performance in peripheral artery disease : The PROPEL Study. / Domanchuk, Kathryn; Ferrucci, Luigi; Guralnik, Jack M.; Criqui, Michael H.; Tian, Lu; Liu, Kiang; Losordo, Douglas; Stein, James; Green, David; Kibbe, Melina; Zhao, Lihui; Annex, Brian; Perlman, Harris; Lloyd-Jones, Donald; Pearce, William; Taylor, Doris; McDermott, Mary M.

In: Contemporary Clinical Trials, Vol. 36, No. 2, 11.2013, p. 502-509.

Research output: Contribution to journalArticle

Domanchuk, K, Ferrucci, L, Guralnik, JM, Criqui, MH, Tian, L, Liu, K, Losordo, D, Stein, J, Green, D, Kibbe, M, Zhao, L, Annex, B, Perlman, H, Lloyd-Jones, D, Pearce, W, Taylor, D & McDermott, MM 2013, 'Progenitor cell release plus exercise to improve functional performance in peripheral artery disease: The PROPEL Study', Contemporary Clinical Trials, vol. 36, no. 2, pp. 502-509. https://doi.org/10.1016/j.cct.2013.09.011
Domanchuk, Kathryn ; Ferrucci, Luigi ; Guralnik, Jack M. ; Criqui, Michael H. ; Tian, Lu ; Liu, Kiang ; Losordo, Douglas ; Stein, James ; Green, David ; Kibbe, Melina ; Zhao, Lihui ; Annex, Brian ; Perlman, Harris ; Lloyd-Jones, Donald ; Pearce, William ; Taylor, Doris ; McDermott, Mary M. / Progenitor cell release plus exercise to improve functional performance in peripheral artery disease : The PROPEL Study. In: Contemporary Clinical Trials. 2013 ; Vol. 36, No. 2. pp. 502-509.
@article{eac5fada61c04d5caab060eeb4173ad5,
title = "Progenitor cell release plus exercise to improve functional performance in peripheral artery disease: The PROPEL Study",
abstract = "Functional impairment, functional decline, and mobility loss are major public health problems in people with lower extremity peripheral artery disease (PAD). Few medical therapies significantly improve walking performance in PAD. We describe methods for the PROgenitor cell release Plus Exercise to improve functionaL performance in PAD (PROPEL) Study, a randomized controlled clinical trial designed to determine whether granulocyte-macrophage colony stimulating factor (GM-CSF) combined with supervised treadmill walking exercise improves six-minute walk distance more than GM-CSF alone, more than supervised treadmill exercise alone, and more than placebo plus attention control in participants with PAD, respectively. PROPEL Study participants are randomized to one of four arms in a 2 by 2 factorial design. The four study arms are GM-CSF plus supervised treadmill exercise, GM-CSF plus attention control, placebo plus supervised exercise therapy, or placebo plus attention control. The primary outcome is change in six-minute walk distance at 12-week follow-up. Secondary outcomes include change in brachial artery flow-mediated dilation (FMD), change in maximal treadmill walking time, and change in circulating CD34. + cells at 12-week follow-up. Outcomes are also measured at six-week and six-month follow-up. Results of the PROPEL Study will have important implications for understanding mechanisms of improving walking performance and preventing mobility loss in the large and growing number of men and women with PAD.",
keywords = "GM-CSF, Intermittent claudication, Peripheral vascular disease, Physical functioning, Stem cells",
author = "Kathryn Domanchuk and Luigi Ferrucci and Guralnik, {Jack M.} and Criqui, {Michael H.} and Lu Tian and Kiang Liu and Douglas Losordo and James Stein and David Green and Melina Kibbe and Lihui Zhao and Brian Annex and Harris Perlman and Donald Lloyd-Jones and William Pearce and Doris Taylor and McDermott, {Mary M.}",
year = "2013",
month = "11",
doi = "10.1016/j.cct.2013.09.011",
language = "English (US)",
volume = "36",
pages = "502--509",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Progenitor cell release plus exercise to improve functional performance in peripheral artery disease

T2 - The PROPEL Study

AU - Domanchuk, Kathryn

AU - Ferrucci, Luigi

AU - Guralnik, Jack M.

AU - Criqui, Michael H.

AU - Tian, Lu

AU - Liu, Kiang

AU - Losordo, Douglas

AU - Stein, James

AU - Green, David

AU - Kibbe, Melina

AU - Zhao, Lihui

AU - Annex, Brian

AU - Perlman, Harris

AU - Lloyd-Jones, Donald

AU - Pearce, William

AU - Taylor, Doris

AU - McDermott, Mary M.

PY - 2013/11

Y1 - 2013/11

N2 - Functional impairment, functional decline, and mobility loss are major public health problems in people with lower extremity peripheral artery disease (PAD). Few medical therapies significantly improve walking performance in PAD. We describe methods for the PROgenitor cell release Plus Exercise to improve functionaL performance in PAD (PROPEL) Study, a randomized controlled clinical trial designed to determine whether granulocyte-macrophage colony stimulating factor (GM-CSF) combined with supervised treadmill walking exercise improves six-minute walk distance more than GM-CSF alone, more than supervised treadmill exercise alone, and more than placebo plus attention control in participants with PAD, respectively. PROPEL Study participants are randomized to one of four arms in a 2 by 2 factorial design. The four study arms are GM-CSF plus supervised treadmill exercise, GM-CSF plus attention control, placebo plus supervised exercise therapy, or placebo plus attention control. The primary outcome is change in six-minute walk distance at 12-week follow-up. Secondary outcomes include change in brachial artery flow-mediated dilation (FMD), change in maximal treadmill walking time, and change in circulating CD34. + cells at 12-week follow-up. Outcomes are also measured at six-week and six-month follow-up. Results of the PROPEL Study will have important implications for understanding mechanisms of improving walking performance and preventing mobility loss in the large and growing number of men and women with PAD.

AB - Functional impairment, functional decline, and mobility loss are major public health problems in people with lower extremity peripheral artery disease (PAD). Few medical therapies significantly improve walking performance in PAD. We describe methods for the PROgenitor cell release Plus Exercise to improve functionaL performance in PAD (PROPEL) Study, a randomized controlled clinical trial designed to determine whether granulocyte-macrophage colony stimulating factor (GM-CSF) combined with supervised treadmill walking exercise improves six-minute walk distance more than GM-CSF alone, more than supervised treadmill exercise alone, and more than placebo plus attention control in participants with PAD, respectively. PROPEL Study participants are randomized to one of four arms in a 2 by 2 factorial design. The four study arms are GM-CSF plus supervised treadmill exercise, GM-CSF plus attention control, placebo plus supervised exercise therapy, or placebo plus attention control. The primary outcome is change in six-minute walk distance at 12-week follow-up. Secondary outcomes include change in brachial artery flow-mediated dilation (FMD), change in maximal treadmill walking time, and change in circulating CD34. + cells at 12-week follow-up. Outcomes are also measured at six-week and six-month follow-up. Results of the PROPEL Study will have important implications for understanding mechanisms of improving walking performance and preventing mobility loss in the large and growing number of men and women with PAD.

KW - GM-CSF

KW - Intermittent claudication

KW - Peripheral vascular disease

KW - Physical functioning

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=84885936001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885936001&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2013.09.011

DO - 10.1016/j.cct.2013.09.011

M3 - Article

VL - 36

SP - 502

EP - 509

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

IS - 2

ER -